Claims for Patent: 9,487,530

Summary for Patent: 9,487,530

Title:	Transient protection of normal cells during chemotherapy
Abstract:	This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
Inventor(s):	Strum; Jay Copeland (Hillsborough, NC), Bisi; John Emerson (Apex, NC), Roberts; Patrick Joseph (Durham, NC), Tavares; Francis Xavier (Durham, NC)
Assignee:	G1 Therapeutics, Inc. (Chapel Hill, NC)
Application Number:	14/212,430
Patent Claims:	1. A method of reducing the effect of chemotherapy on healthy cells in a subject being treated for cyclin-dependent kinase 4/6 (CDK4/6) replication independent cancer or abnormal cell proliferation, wherein said healthy cells are hematopoietic stem cells or hematopoietic progenitor cells, the method comprising administering to the subject an effective amount of at least one chemotherapeutic agent and a compound of the formula: ##STR00329## or a pharmaceutically acceptable salt thereof. 2. A method of reducing the effect of chemotherapy on healthy cells in a subject being treated for cyclin-dependent kinase 4/6 (CDK4/6) replication independent cancer or abnormal cell proliferation, wherein said healthy cells are hematopoietic stem cells or hematopoietic progenitor cells, the method comprising administering to the subject an effective amount of at least one chemotherapeutic agent and a compound of the formula: ##STR00330## wherein R is C(H)X, NX, C(H)Y, or C(X).sub.2; where X is a straight, branched or cyclic C.sub.1 to C.sub.5 alkyl group, and Y is NR.sub.1R.sub.2 wherein R.sub.1 and R.sub.2 are independently X, or wherein R.sub.1 and R.sub.2 are alkyl groups that together form a bridge that includes one or two heteroatoms (N,O, or S); and wherein two X groups can together form an alkyl bridge or a bridge that includes one or two heteroatoms (N, S, or O) to form a spiro compound; or a pharmaceutically acceptable salt thereof. 3. The method of claim 2, wherein the compound is: ##STR00331## or a pharmaceutically acceptable salt thereof. 4. The method of claim 2, wherein the compound is: ##STR00332## or a pharmaceutically acceptable salt thereof. 5. The method of claim 2, wherein the compound is: ##STR00333## or a pharmaceutically acceptable salt thereof. 6. The method of claim 1, wherein the subject is a human. 7. The method of claim 2, wherein the subject is a human. 8. The method of claim 6, wherein the compound is administered to the subject about 24 hours or less prior to exposure to the at least one chemotherapeutic agent. 9. The method of claim 7, wherein the compound is administered to the subject about 24 hours or less prior to exposure to the at least one chemotherapeutic agent. 10. The method of claim 6, wherein the subject has cancer. 11. The method of claim 7, wherein the subject has cancer. 12. The method of claim 6, wherein the subject has an abnormal cell proliferative condition. 13. The method of claim 7, wherein the subject has an abnormal cell proliferative condition. 14. The method of claim 6, wherein the compound is administered to the subject about 4 hours or less prior to exposure to the at least one chemotherapeutic agent. 15. The method of claim 7, wherein the compound is administered to the subject about 4 hours or less prior to exposure the at least one chemotherapeutic agent. 16. The method of claim 10, wherein the cancer is characterized by a loss or absence of the retinoblastoma tumor suppressor protein (RB). 17. The method of claim 11, wherein the cancer is characterized by a loss or absence of the retinoblastoma tumor suppressor protein (RB). 18. The method of claim 10, wherein the cancer is small cell lung cancer, retinoblastoma, triple negative breast cancer, human papillomavirus (HPV) positive head and neck cancer, HPV positive cervical cancer, or bladder cancer. 19. The method of claim 11, wherein the cancer is small cell lung cancer, retinoblastoma, triple negative breast cancer, human papillomavirus (HPV) positive head and neck cancer, HPV positive cervical cancer, or bladder cancer. 20. The method of claim 6, wherein the at least one chemotherapeutic agent is selected from an alkylating agent, DNA intercalator, protein synthesis inhibitor, inhibitor of DNA or RNA synthesis, DNA base analog, topoisomerase inhibitor, telomerase inhibitor, or telomeric DNA binding compound. 21. The method of claim 7, wherein the at least one chemotherapeutic agent is selected from an alkylating agent, DNA intercalator, protein synthesis inhibitor, inhibitor of DNA or RNA synthesis, DNA base analog, topoisomerase inhibitor, telomerase inhibitor, or telomeric DNA binding compound. 22. The method of claim 18, wherein the cancer is small cell lung cancer and the at least one chemotherapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, or topotecan, or a combination thereof. 23. The method of claim 19, wherein the cancer is small cell lung cancer and the at least one chemotherapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, or topotecan, or a combination thereof. 24. The method of claim 6, wherein at least 80% or more of the hematopoietic stem cells or hematopoietic progenitor cells in the subject return to their pre-administration baseline cell-cycle activity within less than about 36 hours from the last administration of the compound. 25. The method of claim 7, wherein at least 80% or more of the hematopoietic stem cells or hematopoietic progenitor cells in the subject return to their pre-administration baseline cell-cycle activity within less than about 36 hours from the last administration of the compound. 26. The method of claim 6, wherein the dissipation of the compound's CDK4/6 inhibitory effect occurs in less than 36 hours from the administration of the compound. 27. The method of claim 7, wherein the dissipation of the compound's CDK4/6 inhibitory effect occurs in less than 36 hours from the administration of the compound. 28. The method of claim 22, wherein the at least one chemotherapeutic agent is etoposide. 29. The method of claim 22, wherein the at least one chemotherapeutic agent is cisplatin. 30. The method of claim 22, wherein the at least one chemotherapeutic agent is carboplatin. 31. The method of claim 22, wherein the at least one chemotherapeutic agent is topotecan. 32. The method of claim 23, wherein the at least one chemotherapeutic agent is etoposide. 33. The method of claim 23, wherein the at least one chemotherapeutic agent is cisplatin. 34. The method of claim 23, wherein the at least one chemotherapeutic agent is carboplatin. 35. The method of claim 23, wherein the at least one chemotherapeutic agent is topotecan. 36. A method of reducing the effect of chemotherapy on healthy cells in a subject being treated for cyclin-dependent kinase 4/6 (CDK4/6) replication independent cancer, wherein said healthy cells are hematopoietic stem cells or hematopoietic progenitor cells, the method comprising administering to the subject an effective amount of at least one chemotherapeutic agent and a compound of the formula: ##STR00334## or a pharmaceutically acceptable salt thereof. 37. The method of claim 36, wherein the subject is a human. 38. The method of claim 37, wherein the compound is administered to the subject about 24 hours or less prior to exposure to the at least one chemotherapeutic agent. 39. The method of claim 37, wherein the compound is administered to the subject about 4 hours or less prior to exposure to the at least one chemotherapeutic agent. 40. The method of claim 37, wherein the cancer is characterized by a loss or absence of the retinoblastoma tumor suppressor protein (RB). 41. The method of claim 37, wherein the cancer is small cell lung cancer, retinoblastoma, triple negative breast cancer, human papillomavirus (HPV) positive head and neck cancer, HPV positive cervical cancer, or bladder cancer. 42. The method of claim 41, wherein the cancer is small cell lung cancer. 43. The method of claim 37, wherein the at least one chemotherapeutic agent is selected from an alkylating agent, DNA intercalator, protein synthesis inhibitor, inhibitor of DNA or RNA synthesis, DNA base analog, topoisomerase inhibitor, telomerase inhibitor or telomeric DNA binding compound. 44. The method of claim 42, wherein the at least one chemotherapeutic agent is selected from the group consisting of carboplatin, cisplatin, etoposide, or topotecan, or a combination thereof. 45. The method of claim 44, wherein the at least one chemotherapeutic agent is etoposide. 46. The method of claim 44, wherein the at least one chemotherapeutic agent is cisplatin. 47. The method of claim 44, wherein the at least one chemotherapeutic agent is carboplatin. 48. The method of claim 44, wherein the at least one chemotherapeutic agent is topotecan. 49. The method of claim 37, wherein at least 80% or more of the hematopoietic stem cells or hematopoietic progenitor cells in the subject return to their pre-administration baseline cell-cycle activity within less than about 36 hours from the last administration of the compound. 50. The method of claim 37, wherein the dissipation of the inhibitor's CDK4/6 inhibitory effect occurs in less than 36 hours from the administration of the compound.